ActiQs / Forskning

PUBLIKATIONSREGISTRET

Gå till forskningen.

Publikationsdata från Europe PMC och PubMed. Följ källhänvisningar från ämnesregistret till originalpublikationerna.

Publikationer som ChEBI hänvisar till för mocetinostat. Visa hela publikationsregistret

En publikationsträff är inte en slutsats. Publikationslistan visar bibliografiska uppgifter. Eventuella forskningsutdrag visas separat med originalunderlag. En källhänvisning visar inte i sig effekt, dosering eller säkerhet.

Publikationer i urvalet

26 träffar

Bibliografisk träff 2023-09-27

CSE1L is a negative regulator of the RB-DREAM pathway in p53 wild-type NSCLC and can be targeted using an HDAC1/2 inhibitor.

Duan L, Tadi MJ, Maki CG.

Sci Rep · research support, non-u.s. gov't; research-article; research support, u.s. gov't, non-p.h.s.; journal article; research support, n.i.h., extramural · DOI 10.1038/s41598-023-43218-3

Bibliografisk träff 2023-09-08

Mocetinostat activates Krüppel-like factor 4 and protects against tissue destruction and inflammation in osteoarthritis.

Kawata M, McClatchy DB, Diedrich JK, Olmer M, Johnson KA, Yates JR, Lotz MK.

JCI Insight · research-article; journal article; research support, n.i.h., extramural · DOI 10.1172/jci.insight.170513

Bibliografisk träff 2023-02-08

Mocetinostat in Combination With Durvalumab for Patients With Advanced NSCLC: Results From a Phase I/II Study.

Johnson ML, Strauss J, Patel MR, Garon EB, Eaton KD, Neskorik T, Morin J, Chao R, Halmos B.

Clin Lung Cancer · clinical trial, phase ii; research support, non-u.s. gov't; clinical trial, phase i; journal article · DOI 10.1016/j.cllc.2023.01.013

Bibliografisk träff 2023-01-15

Molecularly targeted epigenetic therapy with mocetinostat in relapsed and refractory non-Hodgkin lymphoma with CREBBP or EP300 mutations: an open label phase II study.

Qualls D, Noy A, Straus D, Matasar M, Moskowitz C, Seshan V, Dogan A, Salles G, Younes A, Zelenetz AD, Batlevi CL.

Leuk Lymphoma · clinical trial, phase ii; research support, non-u.s. gov't; research-article; journal article; research support, n.i.h., extramural · DOI 10.1080/10428194.2022.2164194

Bibliografisk träff 2022-06-09

Clinical and immune correlate results from a phase 1b study of the histone deacetylase inhibitor mocetinostat with ipilimumab and nivolumab in unresectable stage III/IV melanoma.

Weber JS, Levinson BA, Laino AS, Pavlick AC, Woods DM.

Melanoma Res · research support, non-u.s. gov't; research-article; clinical trial, phase i; journal article; research support, n.i.h., extramural · DOI 10.1097/cmr.0000000000000818

Bibliografisk träff 2022-02-01

Isoform-Selective HDAC Inhibitor Mocetinostat (MGCD0103) Alleviates Myocardial Ischemia/Reperfusion Injury Via Mitochondrial Protection Through the HDACs/CREB/PGC-1α Signaling Pathway.

Wang K, Tang R, Wang S, Xiong Y, Wang W, Chen G, Zhang K, Li P, Tang YD.

J Cardiovasc Pharmacol · journal article · DOI 10.1097/fjc.0000000000001174

Bibliografisk träff 2021-11-01

In vitro anti-proliferative effect of capecitabine (Xeloda) combined with mocetinostat (MGCD0103) in 4T1 breast cancer cell line by immunoblotting.

Kaya Çakir H, Eroglu O.

Iran J Basic Med Sci · research-article; journal article · DOI 10.22038/ijbms.2021.58393.12971

Bibliografisk träff 2021-09-01

Histone deacetylase inhibitor, mocetinostat, regulates cardiac remodelling and renin-angiotensin system activity in rats with transverse aortic constriction-induced pressure overload cardiac hypertrophy.

Kim GJ, Jung H, Lee E, Chung SW.

Rev Cardiovasc Med · journal article · DOI 10.31083/j.rcm2203113

Bibliografisk träff 2021-05-01

Mocetinostat suppresses epidural fibrosis following laminectomy by inhibiting myofibroblast activation and increasing apoptosis.

Wu WJ, Wang J, Liang J, Zhou Q, Liang Y.

Eur Rev Med Pharmacol Sci · journal article; retraction notice · DOI 10.26355/eurrev_202105_25801

Tillbakadragen publikation 2020-04-01

Mocetinostat suppresses epidural fibrosis following laminectomy by inhibiting myofibroblast activation and increasing apoptosis.

Wu WJ, Wang J, Liang J, Zhou Q, Liang Y.

Eur Rev Med Pharmacol Sci · retracted publication; research support, non-u.s. gov't; journal article · DOI 10.26355/eurrev_202004_21029

Bibliografisk träff 2020-01-29

Histone deacetylase inhibitor MGCD0103 causes cell cycle arrest, apoptosis, and autophagy in liver cancer cells.

Liao B, Sun Q, Yuan Y, Yin Y, Qiao J, Jiang P.

J Cancer · research-article; journal article · DOI 10.7150/jca.34091

Bibliografisk träff 2019-08-27

Corrigendum to "SARC018_SPORE02: Phase II Study of Mocetinostat Administered with Gemcitabine for Patients with Metastatic Leiomyosarcoma with Progression or Relapse following Prior Treatment with Gemcitabine-Containing Therapy".

Choy E, Ballman K, Chen J, Dickson MA, Chugh R, George S, Okuno S, Pollock R, Patel RM, Hoering A, Patel S.

Sarcoma · published erratum; correction · DOI 10.1155/2019/7608743

Bibliografisk träff 2018-12-20

Mocetinostat for patients with previously treated, locally advanced/metastatic urothelial carcinoma and inactivating alterations of acetyltransferase genes.

Grivas P, Mortazavi A, Picus J, Hahn NM, Milowsky MI, Hart LL, Alva A, Bellmunt J, Pal SK, Bambury RM, O'Donnell PH, Gupta S, Guancial EA, Sonpavde GP, Faltaos D, Potvin D, Christensen JG, Chao RC, Rosenberg JE.

Cancer · clinical trial, phase ii; research support, non-u.s. gov't; research-article; multicenter study; journal article; research support, n.i.h., extramural · DOI 10.1002/cncr.31817

Bibliografisk träff 2018-11-05

Histone deacetylase inhibitor MGCD0103 protects the pancreas from streptozotocin-induced oxidative stress and β-cell death.

Lee HA, Lee E, Do GY, Moon EK, Quan FS, Kim I.

Biomed Pharmacother · journal article · DOI 10.1016/j.biopha.2018.10.163

Bibliografisk träff 2018-10-24

SARC018_SPORE02: Phase II Study of Mocetinostat Administered with Gemcitabine for Patients with Metastatic Leiomyosarcoma with Progression or Relapse following Prior Treatment with Gemcitabine-Containing Therapy.

Choy E, Ballman K, Chen J, Dickson MA, Chugh R, George S, Okuno S, Pollock R, Patel RM, Hoering A, Patel S.

Sarcoma · research-article; journal article · DOI 10.1155/2018/2068517

Bibliografisk träff 2018-09-03

MGCD0103 induces apoptosis and simultaneously increases the expression of NF-κB and PD-L1 in classical Hodgkin's lymphoma.

Huang R, Zhang X, Min Z, Shadia AS, Yang S, Liu X.

Exp Ther Med · research-article; journal article · DOI 10.3892/etm.2018.6677

Bibliografisk träff 2018-07-05

MGCD0103, a selective histone deacetylase inhibitor, coameliorates oligomeric Aβ25-35 -induced anxiety and cognitive deficits in a mouse model.

Huang HJ, Huang HY, Hsieh-Li HM.

CNS Neurosci Ther · research support, non-u.s. gov't; research-article; journal article · DOI 10.1111/cns.13029

Bibliografisk träff 2017-12-13

Phase I/II study of mocetinostat in combination with gemcitabine for patients with advanced pancreatic cancer and other advanced solid tumors.

Chan E, Chiorean EG, O'Dwyer PJ, Gabrail NY, Alcindor T, Potvin D, Chao R, Hurwitz H.

Cancer Chemother Pharmacol · clinical trial, phase ii; research support, non-u.s. gov't; clinical trial, phase i; journal article · DOI 10.1007/s00280-017-3494-3

Bibliografisk träff 2017-11-29

Mocetinostat combined with gemcitabine for the treatment of leiomyosarcoma: Preclinical correlates.

Lopez G, Braggio D, Zewdu A, Casadei L, Batte K, Bid HK, Koller D, Yu P, Iwenofu OH, Strohecker A, Choy E, Lev D, Pollock R.

PLoS One · research-article; journal article · DOI 10.1371/journal.pone.0188859

Bibliografisk träff 2017-04-25

A phase 2 study of mocetinostat, a histone deacetylase inhibitor, in relapsed or refractory lymphoma.

Batlevi CL, Crump M, Andreadis C, Rizzieri D, Assouline SE, Fox S, van der Jagt RHC, Copeland A, Potvin D, Chao R, Younes A.

Br J Haematol · clinical trial, phase ii; research support, non-u.s. gov't; research-article; multicenter study; journal article · DOI 10.1111/bjh.14698

Bibliografisk träff 2015-08-19

The Effect of MGCD0103 on CYP450 Isoforms Activity of Rats by Cocktail Method.

Cai J, Zhang Q, Lin K, Hu L, Zheng Y.

Biomed Res Int · research support, non-u.s. gov't; research-article; journal article · DOI 10.1155/2015/517295

Bibliografisk träff 2015-08-01

Metabolic changes in rats after intragastric administration of MGCD0103 (Mocetinostat), a HDAC class I inhibitor.

Zhang Q, Wu H, Wen C, Sun F, Yang X, Hu L.

Int J Clin Exp Pathol · research support, non-u.s. gov't; research-article; journal article

Bibliografisk träff 2014-03-04

Liquid chromatography mass spectrometry determination of mocetinostat (MGCD0103) in rat plasma and its application to a pharmacokinetic study.

Ma J, Zhang Q, Wang X.

Xenobiotica · journal article · DOI 10.3109/00498254.2014.897012

Bibliografisk träff 2011-10-25

Mocetinostat for relapsed classical Hodgkin's lymphoma: an open-label, single-arm, phase 2 trial.

Younes A, Oki Y, Bociek RG, Kuruvilla J, Fanale M, Neelapu S, Copeland A, Buglio D, Galal A, Besterman J, Li Z, Drouin M, Patterson T, Ward MR, Paulus JK, Ji Y, Medeiros LJ, Martell RE.

Lancet Oncol · clinical trial, phase ii; research support, non-u.s. gov't; research-article; multicenter study; journal article; research support, n.i.h., extramural · DOI 10.1016/s1470-2045(11)70265-0

Bibliografisk träff 2011-05-10

Mocetinostat (MGCD0103): a review of an isotype-specific histone deacetylase inhibitor.

Boumber Y, Younes A, Garcia-Manero G.

Expert Opin Investig Drugs · research-article; review; journal article · DOI 10.1517/13543784.2011.577737

Bibliografisk träff 2007-06-01

Drug evaluation: MGCD-0103, a histone deacetylase inhibitor for the treatment of cancer.

Kell J.

Curr Opin Investig Drugs · review; journal article

Gå till forskningen.

Publikationer i urvalet

CSE1L is a negative regulator of the RB-DREAM pathway in p53 wild-type NSCLC and can be targeted using an HDAC1/2 inhibitor.

Mocetinostat activates Krüppel-like factor 4 and protects against tissue destruction and inflammation in osteoarthritis.

Mocetinostat in Combination With Durvalumab for Patients With Advanced NSCLC: Results From a Phase I/II Study.

Molecularly targeted epigenetic therapy with mocetinostat in relapsed and refractory non-Hodgkin lymphoma with <i>CREBBP</i> or <i>EP300</i> mutations: an open label phase II study.

Clinical and immune correlate results from a phase 1b study of the histone deacetylase inhibitor mocetinostat with ipilimumab and nivolumab in unresectable stage III/IV melanoma.

Isoform-Selective HDAC Inhibitor Mocetinostat (MGCD0103) Alleviates Myocardial Ischemia/Reperfusion Injury Via Mitochondrial Protection Through the HDACs/CREB/PGC-1α Signaling Pathway.

<i>In vitro</i> anti-proliferative effect of capecitabine (Xeloda) combined with mocetinostat (MGCD0103) in 4T1 breast cancer cell line by immunoblotting.

Histone deacetylase inhibitor, mocetinostat, regulates cardiac remodelling and renin-angiotensin system activity in rats with transverse aortic constriction-induced pressure overload cardiac hypertrophy.

Mocetinostat suppresses epidural fibrosis following laminectomy by inhibiting myofibroblast activation and increasing apoptosis.

Mocetinostat suppresses epidural fibrosis following laminectomy by inhibiting myofibroblast activation and increasing apoptosis.

Histone deacetylase inhibitor MGCD0103 causes cell cycle arrest, apoptosis, and autophagy in liver cancer cells.

Corrigendum to "SARC018_SPORE02: Phase II Study of Mocetinostat Administered with Gemcitabine for Patients with Metastatic Leiomyosarcoma with Progression or Relapse following Prior Treatment with Gemcitabine-Containing Therapy".

Mocetinostat for patients with previously treated, locally advanced/metastatic urothelial carcinoma and inactivating alterations of acetyltransferase genes.

Histone deacetylase inhibitor MGCD0103 protects the pancreas from streptozotocin-induced oxidative stress and β-cell death.

SARC018_SPORE02: Phase II Study of Mocetinostat Administered with Gemcitabine for Patients with Metastatic Leiomyosarcoma with Progression or Relapse following Prior Treatment with Gemcitabine-Containing Therapy.

MGCD0103 induces apoptosis and simultaneously increases the expression of NF-κB and PD-L1 in classical Hodgkin's lymphoma.

MGCD0103, a selective histone deacetylase inhibitor, coameliorates oligomeric Aβ<sub>25-35</sub> -induced anxiety and cognitive deficits in a mouse model.

Phase I/II study of mocetinostat in combination with gemcitabine for patients with advanced pancreatic cancer and other advanced solid tumors.

Mocetinostat combined with gemcitabine for the treatment of leiomyosarcoma: Preclinical correlates.

A phase 2 study of mocetinostat, a histone deacetylase inhibitor, in relapsed or refractory lymphoma.

The Effect of MGCD0103 on CYP450 Isoforms Activity of Rats by Cocktail Method.

Metabolic changes in rats after intragastric administration of MGCD0103 (Mocetinostat), a HDAC class I inhibitor.

Liquid chromatography mass spectrometry determination of mocetinostat (MGCD0103) in rat plasma and its application to a pharmacokinetic study.

Mocetinostat for relapsed classical Hodgkin's lymphoma: an open-label, single-arm, phase 2 trial.

Mocetinostat (MGCD0103): a review of an isotype-specific histone deacetylase inhibitor.

Drug evaluation: MGCD-0103, a histone deacetylase inhibitor for the treatment of cancer.